Skip to main content

Table 2 HIV seropositivity in relation to some selected participant characteristics (N = 74)

From: HIV serostatus and tumor differentiation among patients with cervical cancer at Bugando Medical Centre

Characteristic HIV serostatus Total p-value
Positive Negative
Age group
≤50 years 19 (50.0) 19 (50.0) 38 (100.0) <0.001 (Pearson)*
>50 years 3 (8.3) 33 (91.7) 36 (100.0)  
Sub-total 22 (29.7) 52 (70.3) 74 (100.0)  
Clinical stage
Stage IB 5 (20.8) 19 (79.2) 24 (100.0)  
Stage IIA 4 (26.7) 11 (73.3) 15 (100.0)  
Stage IIB 4 (36.4) 7 (63.6) 11 (100.0)  
Stage IIIA 3 (50.0) 3 (50.0) 6 (100.0)  
Stage IIIB 4 (40.0) 6 (60.0) 10 (100.0)  
Stage IVA 2 (25.0) 6 (75.0) 8 (100.0)  
Total 22 (29.7) 52 (70.3) 74 (100.0)  
Stage classification
Early stage (IA-IIA) 9 (23.1) 30 (76.6) 39 (100.0) 0.186 (Pearson)**
Advanced stage (IIB-IVB) 13 (37.1) 22 (62.9) 35 (100.0)  
Total 22 (29.7) 52 (70.3) 74 (100.0)  
Tumor cell differentiation
Well 12 (52.2) 11 (47.8) 23 (100.0) 0.006 (exact)***
Moderate 8 (25.8) 23 (74.4) 31 (100.0)  
Poor 2 (11.1) 16 (88.9) 18 (100.0)  
Total 22 (30.6) 50 (69.4) 72 (100.0)****  
  1. Note: Number in brackets denotes percentages.
  2. *p-value comparing HIV seropositivity between participants aged ≤ 50 years versus those aged over.
  3. **p-value comparing HIV seropositivity between women with early versus late stage disease.
  4. ***p-value comparing participants with well differentiated and combined moderately and poorly differentiated tumor cells.
  5. ****Two patients had small cell carcinoma whose cellular differentiation could not be determined.